A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
暂无分享,去创建一个
Yue Hu | Chao Wang | Huaqiong Huang | Shaojun Jin | Zihan Yi | Cuixia Liu | Xiaohong Pan | Zihan Yi
[1] C. Lionte,et al. The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity , 2022, Life.
[2] M. Ieda,et al. Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature , 2022, Frontiers in Pharmacology.
[3] H. Prenen,et al. Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy , 2021, ESMO open.
[4] M. Kerneis,et al. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. , 2021, JAMA cardiology.
[5] A. Curtis,et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis , 2021, Journal for ImmunoTherapy of Cancer.
[6] L. Galluzzi,et al. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. , 2021, The Journal of clinical investigation.
[7] A. Bojan,et al. Assessment and Management of Cardiotoxicity in Hematologic Malignancies , 2021, Disease markers.
[8] Yong Yi,et al. Recent updates on Sintilimab in solid tumor immunotherapy , 2020, Biomarker research.
[9] J. Holfeld,et al. Cardiotoxic mechanisms of cancer immunotherapy - A systematic review. , 2020, International journal of cardiology.
[10] A. Lyon,et al. The Role of Biomarkers in Cardio-Oncology , 2020, Journal of Cardiovascular Translational Research.
[11] O. Merimsky,et al. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis , 2020, Clinical Research in Cardiology.
[12] Xinchen Sun,et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. , 2020, Chinese clinical oncology.
[13] K. Zheng,et al. Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events , 2020, Thoracic cancer.
[14] R. Sullivan,et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. , 2020, European heart journal.
[15] Huijuan Zhu,et al. Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction , 2020, Thoracic cancer.
[16] J. Durand,et al. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment , 2020, Journal of the American Heart Association.
[17] P. Sharma,et al. Dissecting the mechanisms of immune checkpoint therapy , 2020, Nature Reviews Immunology.
[18] Jen‐Shi Chen,et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.
[19] Mengzhao Wang,et al. Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis , 2019, Thoracic cancer.
[20] Bo Peng,et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit , 2019, mAbs.
[21] Marc P. Bonaca,et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology , 2019, Circulation.
[22] Bijie Hu,et al. Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma. , 2019, Annals of translational medicine.
[23] L. Cooper,et al. Management of Myocarditis-Related Cardiomyopathy in Adults. , 2019, Circulation research.
[24] Y. Shimizu,et al. Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature , 2019, Internal medicine.
[25] P. Queirolo,et al. Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Lipson,et al. Cardiovascular toxicities associated with immune checkpoint inhibitors , 2019, Cardiovascular research.
[27] Marc P. Bonaca,et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.
[28] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.
[29] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[30] G. Soulat,et al. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. , 2018, European heart journal.
[31] T. Neilan,et al. Immune Checkpoint Inhibitor-Associated Myocarditis. , 2018, The oncologist.
[32] M. Mussap,et al. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. , 2018, The oncologist.
[33] Syed S Mahmood,et al. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report , 2018, Gynecologic oncology reports.
[34] R. Sullivan,et al. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action , 2018, The oncologist.
[35] R. Sullivan,et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. , 2018, Journal of the American College of Cardiology.
[36] J. Brahmer,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.
[37] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] W. Ullah,et al. New drugs and new toxicities: pembrolizumab-induced myocarditis , 2018, BMJ Case Reports.
[39] J. Grob,et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. , 2017, Circulation.
[40] G. Pontone,et al. Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With Preserved Systolic Function: ITAMY Study. , 2017, Journal of the American College of Cardiology.
[41] R. Blankstein,et al. Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. , 2017, Journal of the American College of Cardiology.
[42] J. Sosman,et al. Myocarditis with Immune Checkpoint Blockade. , 2017, The New England journal of medicine.
[43] J. Seidman,et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.
[44] Andreas Wicki,et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study , 2016, Journal of Immunotherapy for Cancer.
[45] M. Bossard,et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.
[46] Tiina Heliö,et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.
[47] Jen‐Shi Chen,et al. Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword. , 2013, Acta Cardiologica Sinica.
[48] Matthias Gutberlet,et al. Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .
[49] J. Schulz-Menger,et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. , 2005, Journal of the American College of Cardiology.
[50] O Strohm,et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. , 1998, Circulation.